Back to Agenda
Session 6: COVID-19 Learnings: Research Done Differently
Session Chair(s)
Daniel Millar, MBA
Senior Director, Strategic Business Transformation, Johnson & Johnson, United States
The value of Master Protocols has become understood and accepted through unprecedented multi-stakeholder response to the COVID-19 pandemic. Over 300 clinical studies were set up in record time, including several Master Protocols for both therapeutics and vaccines. Suddenly, the ability to form productive consortia became a critical path challenge to implement quantitative innovations provided by Master Protocols. This session will focus on the underlying trends transforming Master Protocol studies and clinical research.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify the role of Master Protocols in COVID-19 therapeutic and vaccine development
- Identify recent developments in stakeholders’ attitudes and perceptions of Master Protocol studies
- Identify factors that will influence the successful design and implementation of Master Protocol studies
Speaker(s)
Lennie Derde, MD, PHD
Intensivist and Clinician Researcher, UMC Utrecht, Netherlands
Speaker
Janice Chang
Chief Executive Officer , TransCelerate Biopharma Inc., United States
Catalyzing Innovation Through Collaboration
Lisa LaVange, PHD
Professor Emerita, University of North Carolina at Chapel Hill, United States
Speaker
Tobias Mielke, PHD
Janssen Pharmaceutical, Scientific Director, Germany
When Time Matters Most: Converting a Traditional Study into a Master Protocol in One Week
Have an account?